MDGL Q4 2024 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$103M

Gross Profit

$100M96.7% margin

Operating Income

-$67M-64.8% margin

Net Income

-$59M-57.5% margin

EPS (Diluted)

$-2.71

QoQ Revenue Growth

+66.2%

Cash Flow

Operating Cash Flow

-$104M

Free Cash Flow

-$105M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$288M

Stockholders' Equity

$754M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$0	—
Gross Profit	$100M	$0	—
Operating Income	-$67M	-$117M	+42.8%
Net Income	-$59M	-$112M	+47.0%